EP0708639A4 - Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (+) optiquement pure - Google Patents

Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (+) optiquement pure

Info

Publication number
EP0708639A4
EP0708639A4 EP93915449A EP93915449A EP0708639A4 EP 0708639 A4 EP0708639 A4 EP 0708639A4 EP 93915449 A EP93915449 A EP 93915449A EP 93915449 A EP93915449 A EP 93915449A EP 0708639 A4 EP0708639 A4 EP 0708639A4
Authority
EP
European Patent Office
Prior art keywords
sibutramine
disorders
compositions
methods
optically pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93915449A
Other languages
German (de)
English (en)
Other versions
EP0708639A1 (fr
Inventor
James W Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of EP0708639A1 publication Critical patent/EP0708639A1/fr
Publication of EP0708639A4 publication Critical patent/EP0708639A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP93915449A 1992-06-23 1993-06-22 Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (+) optiquement pure Withdrawn EP0708639A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90303492A 1992-06-23 1992-06-23
US903034 1992-06-23
PCT/US1993/005967 WO1994000047A1 (fr) 1992-06-23 1993-06-22 Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (+) optiquement pure

Publications (2)

Publication Number Publication Date
EP0708639A1 EP0708639A1 (fr) 1996-05-01
EP0708639A4 true EP0708639A4 (fr) 1997-08-20

Family

ID=25416828

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93915449A Withdrawn EP0708639A4 (fr) 1992-06-23 1993-06-22 Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (+) optiquement pure

Country Status (5)

Country Link
EP (1) EP0708639A4 (fr)
JP (1) JPH07508281A (fr)
AU (1) AU4542993A (fr)
CA (1) CA2139000A1 (fr)
WO (1) WO1994000047A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
MXPA01009461A (es) * 1999-03-19 2004-03-19 Abbott Gmbh & Co Kg Tratamiento de osteoartritis.
CA2368083A1 (fr) 1999-04-06 2000-10-12 Sepracor Inc. Derives de la venlafaxine et leurs procedes de preparation et utilisation
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
DK1360169T3 (da) 2001-02-12 2007-11-26 Wyeth Corp Succinatsalt af O-desmethyl-venlafaxin
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008993A1 (de) * 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
GB2098601B (en) * 1981-04-02 1985-07-24 Sandoz Products Ltd Improvements in or relating to organic compounds
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9400047A1 *

Also Published As

Publication number Publication date
AU4542993A (en) 1994-01-24
EP0708639A1 (fr) 1996-05-01
CA2139000A1 (fr) 1994-01-06
WO1994000047A1 (fr) 1994-01-06
JPH07508281A (ja) 1995-09-14

Similar Documents

Publication Publication Date Title
EP0647134A4 (fr) Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure.
AU2287495A (en) Methods and compositions for treating depression and other disorders using optically pure s(+) fluoxetine
EP0708639A4 (fr) Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (+) optiquement pure
EP0748220A4 (fr) Procedes et compositions de traitement de maladies dependantes des androgenes a l'aide de r-(-)-casodex optiquement pur
GB9525977D0 (en) Perfluoroelastomeric compositions and methods
GR3026535T3 (en) Water-dispersible adhesive composition and process
ZA934341B (en) Methods and compositions for enhancing carbon fixation in plants
EP0695123A4 (fr) Procedes et compositions permettant de traiter des troubles gastriques au moyen de pantoprazole (-) optiquement pur
GB9208339D0 (en) Treatment composition
EP0695224A4 (fr) Compositions et procedes de traitement de dechets
EP0591303A4 (en) Methods and compositions for treating malaria and other diseases
IL109280A0 (en) Neurotrophins for treatment of depression
HUP0003488A3 (en) Methods and compsitions for treating pulmonary disorders using optically pure (s)-salmeterol
EP0700292A4 (fr) Procedes et compositions de traitement de troubles gastriques a l'aide de pantoprazole (+) optiquement pur
AU3245593A (en) Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
EP0711159A4 (fr) Procedes et compositions de traitement de l'asthme, de l'atherosclerose et de maladies inflammatoires a l'aide de (-)-zileuton optiquement pur
EP0585168A3 (en) Composition and methods for the generation of bone
AU6599196A (en) Compositions containing analgesics and antihistamines and methods for treating respiratory disorders
HU9400129D0 (en) Process for blending of adhesive consisting of two components
AU696392B2 (en) Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
GB2281987B (en) Clock distributing methods and apparatus
EP0708638A4 (fr) Procedes et compositions servant a traiter la depression et d'autres maladies psychiatriques
GB9420539D0 (en) Process and composition
AU1658992A (en) Methods and compositions for treating pulmonary disorders using optically pure terbutaline
AU4529897A (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: A61K 31/135

A4 Supplementary search report drawn up and despatched

Effective date: 19970704

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19991119

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEPRACOR INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050101